Nuclear Medicine- Table of Contents

Apr 2, 2002

Nuclear Medicine- Table of Contents

Scott C. Williams, MD

Contributors

General Nuclear Medicine

Cardiac Imaging

Central Nervous System

Endocrine: Thyroid & Parathyroid

Genitourinary

Gastrointestinal

Infection and Inflammation

Musculoskeletal: Bone/Soft Tissues and Lymphatics

Positron Emission Tomography (PET)

Pulmonary

Tumor Imaging and Radionuclide Therapy

Radioscintigraphic Assay and Volumetry (RIA)

Radiation Biology

(C) 1995- Scott Williams, M.D.

Representative Ga-68 FAPI-PET/CT images of 48-year-old woman who had left invasive ductal carcinoma and who achieved pathologic complete response (pCR). (A) Baseline maximum-intensity projection (MIP) image demonstrated primary lesion (red arrowhead; SUVmax, 26.72) and Ga-68 FAPI-avid lymph node in left axilla (red arrows). (B) MIP image after two cycles of neoadjuvant chemotherapy (NAC) showed that primary lesion (red arrowhead; SUVmax, 8.87) and axillary lymph nodes (red arrow) were reduced in size and radioactivity uptake. (C and D) Representative images of lab tissue staining for FAP before NAC showed strong FAP-positive staining in stromal cells (C), which was significantly decreased on tumor bed after six cycles of NAC (D). Image courtesy of the Journal of Nuclear Medicine.

PET predicts chemotherapy responses in breast cancer patients

November 8, 2023

Theranostics for personalized cancer care

Theranostics for personalized cancer care

November 1, 2023

PET reveals patient responses to new Alzheimer’s disease drug

October 27, 2023

Pediatric PET radiotracer doses drop by a third over two decades

October 20, 2023

PET predicts chemotherapy responses in breast cancer patients

PET/CT with gallium-68 FAPI radiotracer can predict responses to neoadjuvant chemotherapy in breast cancer patients.

November 8, 2023

Representative Ga-68 FAPI-PET/CT images of 48-year-old woman who had left invasive ductal carcinoma and who achieved pathologic complete response (pCR). (A) Baseline maximum-intensity projection (MIP) image demonstrated primary lesion (red arrowhead; SUVmax, 26.72) and Ga-68 FAPI-avid lymph node in left axilla (red arrows). (B) MIP image after two cycles of neoadjuvant chemotherapy (NAC) showed that primary lesion (red arrowhead; SUVmax, 8.87) and axillary lymph nodes (red arrow) were reduced in size and radioactivity uptake. (C and D) Representative images of lab tissue staining for FAP before NAC showed strong FAP-positive staining in stromal cells (C), which was significantly decreased on tumor bed after six cycles of NAC (D). Image courtesy of the Journal of Nuclear Medicine.

FAPI-PET bests FDG-PET in detecting gastrointestinal cancer

Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer.

October 31, 2023

Nine representative patients who underwent F-18 FDG and F-18 FAPI-74 PET imaging. F-18 FAPI-74 PET outperforms F-18 FDG-PET in detecting primary tumors (patients 11, 39, 50, 58, 79, and 101; solid black arrows), local recurrences (patient 4; blue arrows), abdomen LN metastases (patients 4 and 50; green arrows), intrahepatic metastases (patient 50; red arrows), bone metastases (patient 85; arrowheads), and peritoneal metastases (patients 4, 11, 85, 97, and 101; dotted arrows). Image courtesy of the Journal of Nuclear Medicine.

PET reveals patient responses to new Alzheimer’s disease drug

Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab.

October 27, 2023

Pediatric PET radiotracer doses drop by a third over two decades

Over the past 20 years, children have benefited from a massive reduction in PET imaging radiotracer doses without compromise in image quality.

October 20, 2023

Researchers offer hypothesis for long COVID brain fog

A group in France has offered an explanation for long COVID brain fog, with the concept based on a visual brain pattern they discovered on patient PET scans.

October 19, 2023

Hypometabolism detected with F-18 FDG-PET in long-COVID patients: putative astrocyte dysfunction and glutamatergic dysregulation. (A) PET scan of a healthy subject. (B) PET scan of a long COVID patient. Hypometabolic areas are indicated with arrows. (C) A diagram showing a healthy condition in which an astrocyte has a normal capacity to take up glutamate and recycle it to sustain glutamatergic neurotransmission, giving rise to normal glucose utilization and lactate production to ensure adequate neuronal energy supply. (D) A diagram showing a long COVID condition in which an astrocyte has reduced glutamate uptake capacity, leading to reduced glutamate recycling, lower glucose utilization (observed with F-18 FDG-PET as hypometabolism) and lower lactate production, dysregulating glutamatergic neurotransmission, and possibly endangering neuronal survival.

TRIGA reactor fuel supply restored in the U.S

Pennsylvania State University has received the first TRIGA nuclear research reactor fuel delivery in the U.S. in a decade.

October 12, 2023

Penn State received the TRIGA reactor fuel on September 27.

Does a dedicated PET prostate cancer scanner have clinical potential?

A recently built small PET scanner may improve the detection of prostate cancer and could ultimately reduce invasive patient biopsies to confirm disease.

October 6, 2023

A photograph of the detector ring of the ProsPET system.

IAEA's Rays of Hope initiative establishes anchor centers

Rays of Hope – the International Atomic Energy Agency's (IAEA) flagship cancer initiative – has named inaugural "anchor centers" in five countries.

September 29, 2023

'Hype' is over for PET/MRI, experts say

PET/MRI has entered the "Slope of Enlightenment" phase of the Gartner Hype Cycle, according to experts.

September 26, 2023

The Gartner Hype Cycle

Rare finding detected on PSMA-PET: A nonprostatic lung tumor

A group in Australia has described a rare finding during a prostate cancer restaging PET/CT scan – a pulmonary tumor embolism.

September 25, 2023

Hybrid contrast-enhanced CT (with iodinated contrast bolus timed to maximize pulmonary arterial visualization) and F-18 DCFPyL PSMA-PET images. Contrast CT images (A, B) show an eccentric filling defect in the superior lingula segmental artery of the left lung upper lobe (red arrow). This is concordant with moderately intense PSMA radiotracer expression (black arrows on axial PET-only images, C, and on whole-body maximum intensity projection image, E). Fused PET and contrast-enhanced CT axial image (D) also confirm the lesion (red arrow). No other site of PSMA expressing metastasis is evident on whole-body imaging (E).

Is Pylarify better than Ga-68 PSMA-11 for prostate cancer imaging?

Subtle differences in how PSMA-PET radiotracers perform in patients before Pluvicto treatment may determine which become the future tracers of choice.

September 22, 2023

PSMA-PET imaging

ADNI aims to increase diversity in clinical trials.

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has launched its latest study with a focus on enrolling a more diverse population.

September 15, 2023

Am 2022 01 12 18 18 1479 Patient Elderly Confused Headache 400

Page 1 of 435